Integra LifeSciences

Q2 FY2026 EarningsQ2 FY2026 results delivered a double-beat, with reported revenue of $418.8M slightly edging out the $417.5M consensus and adjusted EPS of $0.56 significantly exceeding the $0.48 mean estimate. Specialty Surgery grew 1.6% organically, offsetting a 2.0% decline in Tissue Reconstruction caused by supply transitions. While the full-year organic growth guidance was reaffirmed at 0.8%-3.3%, the reported revenue outlook was lowered to $1.654B-$1.695B solely to account for FX headwinds, maintaining a solid fundamental trajectory with the Braintree facility now operational.